The EU Commission publishes its findings of the evaluation of procedural and jurisdictional aspects of EU merger control and new guidance on the application of Article 22 of the EU Merger Regulation

On 26 March, the European Commission (“EC”) published its findings of the evaluation of procedural and jurisdictional aspects of EU merger control, and new guidance on the application of Article 22 of the EU Merger Regulation (“EUMR”) [1] encouraging Member States to refer more transactions to the EC for review, even where the transaction does not meet any EU or national thresholds. The EC explicitly singled out the digital and pharma/biotech sectors as areas in which potentially anticompetitive mergers have escaped scrutiny, leading the EC to revise its policy on Article 22 EUMR [2]. Referrals may be requested in relation to both proposed and completed transactions. Baker Botts’ Life Sciences Antitrust and Competition team noted this abrupt shift in EU merger control policy and discusses

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Baker Botts (Brussels)
  • Baker Botts (Brussels)
  • Baker Botts (Washington)
  • Baker Botts (Brussels)

Quotation

Matthew Levitt, Paul Lugard, Jody Boudreault, Roxane Tonnelier, The EU Commission publishes its findings of the evaluation of procedural and jurisdictional aspects of EU merger control and new guidance on the application of Article 22 of the EU Merger Regulation, 26 March 2021, e-Competitions March 2021, Art. N° 101811

Visites 163

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues